Industry: Health Care – Biotechnology: Pharmaceutical Preparations
Stock Symbol: ABP – NASDAQ
Animal Usage: Animal Testing
Abpro Holdings Inc is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
Supporting Evidence:
The company stated in the following press release that they use animals for product testing.
“The results from our preclinical study are very encouraging for the potential of ABP201 to treat patients affected by Wet AMD and DME,” said Ian Chan, chief executive officer of Abpro. “Bispecific antibody-based treatments for vascular diseases of the eye are promising. This data, which demonstrate equal or better performance to the standard of care in these animal models of neovascularization, is a significant step forward in the company’s ophthalmology program and warrants further evaluation of ABP201 in clinical, in-human studies.” Read the following article
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Company website: https://abpro.co